



ransEnterix®



Todd M. Pope President & CEO

Stifel 2017 Healthcare Conference

November 14, 2017



Forward Looking Statements

This presentation includes statements relating to TransEnterix's current regulatory and commercialization plans for our products, the Senhance™ Surgical Robotic System and the SurgiBot™ System. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the commercialization of the Senhance Surgical Robotics System will be successful, whether and when we will prepare a 510(k) submission for the Senhance Surgical Robotic System, the pace of adoption of our products by surgeons, the success and market opportunity of our products, our current cash reach, the effect on our business of existing and new regulatory requirements and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our including our Annual Report on Form 10-K filed on March 6, 2017 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of the presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.





TransEnterix: TRXC

4

Focus: Surgical Robotics

Compelling Platform Technology

- Senhance Surgical Robot
- Robotic benefits with responsible economics

Significant addressable market opportunity

- Surgical robotics growing but minimally penetrated

Recent highlights


- Senhance FDA clearance obtained Oct '17
- Sold first unit in U.S. Nov '17
- Expanded portfolio to include 3mm micro instruments and leading vision systems





Surgical Robotics Poised for Growth

Abdominal Robotic Surgery Market Size




Procedure expansion, geographic expansion and new entrants will grow abdominal robotic surgery market significantly






Benefits of Surgical Robotics





Robotic Surgery Landscape



Historical Growth Drivers:

- Convert open surgeries to robotics
- Clinical and patient benefits have come from converting an open procedure to a minimally-invasive surgical approach
- Offset significant per-procedure cost increase with length of stay benefit vs. open surgery
- Conversion of laparoscopy to robotics difficult due to substantial per-procedure cost increase


Sources: Intuitive Surgical Investor Slides, TRXC Estimates and Millennium Research Group





Robotic Surgery Landscape

8



Future Growth Drivers:

- Convert laparoscopic surgeries to robotics
- Opportunities to improve laparoscopy: greater precision, surgeon control of vision, better ergonomics, reduced need for assistance
- Provide meaningful robotic benefits to laparoscopic surgery without significant per-procedure cost increase

Sources: Intuitive Surgical Investor Slides, TRXC Estimates and Millennium Research Group



Senhance Surgery Robotic Benefits



SenhanceSurgery





Unmet Need Exists for a Robotic System that Addresses the Laparoscopic Market

10

Laparoscopic Value Historically a Barrier for Robotics:

- Highly efficient operations
- Excellent patient outcomes
- Low per-procedure costs



Limitations of Laparoscopy:

- Reliance on assistant to control camera
- Challenging ergonomics
- Imprecise instrument movement
- Difficulty suturing
- Torque at incision sites

Hospitals Under Market Pressure:

- Concerned about robotics increasing procedure costs
- Patients are seeking robotic options
- Hospitals feel pressured to offer robotic option or lose valuable incremental volume and surgeon engagement





Senhance is Uniquely Positioned to Address Laparoscopic Market



Maintain O.R. Efficiency



Maintain MIS standards



Responsible Economics

Familiar lap technique

Rapid docking for ease of setup

Ease of patient re-positioning

Retain 5-mm instruments

Security of haptic feedback

Haptics allows for minimal incision trauma

Reusable instruments maintain procedural costs similar to laparoscopy



Senhance Robotic Benefits

Precision

Ergonomics

Advanced Instrumentation

Eye-sensing camera control



Senhance Robotic Inguinal Hernia Repair
Left side, TAPP, Lateral and Medial Hernias

Dr. Dietmar Stephan, St. Marien Krankenhaus
Siegen, Germany

Department of Minimally Invasive and Robotic Surgery
Clinic of General Surgery, Chief Prof. Dr. F. Willeke



Senhance FDA Cleared

13


- Senhance received FDA clearance Oct 13
 - Clinical data on ~200 procedures submitted
 - Six-month review cycle
- First new entrant to soft tissue robotics since 2000
- Cleared for colorectal and gynecological laparoscopic surgery
 - Indications cover 23 procedures
 - Covers benign and oncologic treatments
- Initial market 1.5 million US procedures





Commercial Activity - US

- Sales resources
 - 17 sales professionals
 - Majority of 20 largest MSAs covered
 - Established innovation center at the Institute for Surgical Advancement at Florida Hospital Orlando Q3 '17
 - Strong presence at major trade shows
- Sales activities
 - First sale to Florida Hospital Orlando Q4 '17
 - Anticipate 4-6 quarter capital sales cycle





Commercial Activity - OUS

- Strong foundation established
 - Direct sales team covering Germany, France & UK
 - Distributors and agents expand coverage to other markets
- Sales activities
 - Italian first sale Q3 '16
 - German first sale in Q1 '17
 - Japan first sale Q2 '17
 - Taiwan first sale Q3 '17





Product and Clinical Milestones

16

Instruments	European Launch	US Launch
3mm Instruments	4Q-2017	2018
Advanced Energy	2018	2018
Articulated Instruments	2018	2018

FDA Indication Expansion

Procedures	Timing	Impact
Hernia & Cholecystectomy	Submitting to FDA in early 1Q-2018	Doubles addressable market





Building Clinical Evidence

- Peer-reviewed published data on procedures for benign and malignant disease and in obese patients
- Surgeons cite positives of short learning curve & median 7 minute set-up time
- Feasibility, safety profile and procedural economics similar to lap surgery for procedures investigated

Journal Reference	Patients	Study Findings
In process – hernia	64	Positive safety & efficacy profile in hernia repair, short learning curve and docking time
In process – cholecystectomy	20	Positive safety & efficacy profile in cholecystectomy,
Accepted – colorectal	47	Positive safety & efficacy profile in colorectal
Fanfani F, et al. Surg Endosc. 2015	146	Positive safety & efficacy profile in a range of gynecologic surgical procedures
Fanfani F, et al. J Minim Invasive Gynecol. 2015	80	Similar safety & efficacy profile to laparoscopy in hysterectomy
Rossetto C, et al. Int J Med Robot. 2016	81	Robotic benefits with responsible economics for the laparoscopic hysterectomy
Gueli Alletti S, et al. J Minim Invasive Gynecol. 2015	43	Similar safety & efficacy profile to laparoscopy for early-stage endometrial cancer
Gueli Alletti S, et al. J Minim Invasive Gynecol. 2015	10	Positive safety & efficacy profile in ovarian cyst enucleation
Rossetto C, et al. J Robot Surg. 2016	10	Positive safety & efficacy profile in obese hysterectomy patients





Financial

- Year-to-date Sep '17 revenue - \$3.7M
 - Expect at least 2 system sales in Q4
- October 31, 2017 cash and restricted cash - \$100.7M
- Adequate to fund operations beyond 2018
- Well positioned for expanded US commercialization efforts and to continue to invest in other geographies



2017 Key Priorities


Continued focus on commercialization efforts in CE Mark countries



Obtain Senhance US 510(k) clearance by year end



Continue to demonstrate clinical success across multiple specialties and procedures



Prepare for U.S. launch pending FDA clearance with focused market development activities





ransEnterix®